Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More news from MYMD
https://ir.mymd.com/news-events/press-releases/detail/36/mymd-pharmaceuticals-to-collaborate-with-bascom-palmer-eye
Note that the relationship is fully funded by BASCOM EYE!
I want some 2.82s
Is NO one following this company MYMD they seem to have groundbreaking events about to happen over and over again with approvals, I am buying whatever I can down here, it's almost like it's too true to believe but here we are. If I am missing something seriously let me know LOL. TIA
GLTA MYMD ( It will be a wild ride for all)
MYMD $$$$$
Closed up 42% today according to thinkorswim (TD Ameritrade)
Here's the news!!!!!
https://seekingalpha.com/news/3855420-oramed-mymd-surge-on-plans-for-early-stage-oral-covid-vaccine-data-release-in-q3?utm_source=stck.pro&utm_medium=referral
My bad, see post 286 ! Seems like the Covid pill is alive and well!
"Looking for", or maybe "hoping for" would be more appropriate, MyMD Pharma to make a big splash in 2022's 2nd half beginning with the 5 to 6 minute video introducing MyMD Pharmaceuticals to the American public with presentations on numerous TV channels. Following up with early results of the Phase 2 post Covid depression study which indicates that MYMD-1 not only knocks down post Covid depression, but also appears to block "long Covid".
Follow this up with the publication in a highly respected medical journal with the results of the pre-clinical MYMD-1, healthy life extension rat study which highlights the survival rate of the strong and healthy "immortal rats". Along with this, provide the early results of the Phase 2 human study of over sixty-fivers diagnosed with sarcopenia who were treated with MYMD-1.
Next, have MyMD Pharma personnel brief The Arthritis Foundation on a planned Phase 2 study challenging subjects with Rhuematoid Arthritis with MYMD-1, then contact Iquvia to lead the study, hopefully financed in part by Arthritis Foundation funding.
Lastly, highlight the soon to begin Phase 2 studies challenging Hasimoto's Thyroiditis, Multiple Sclerosis, and Type 2 Diabetes with MYMD-1. If this doesn't light a fire under MYMD, then nothing will.
Looking like Oravax and its Covid 19 vaccine pill have dropped out of sight! There has been no word abought them since testing of the pill began in South Africa, and a presentation by Oramed in mid-May made no mention of the Oravax pill.
If anyone knows more about it please let us know.
I posted the following on the rcpiq board. No answer. Tree falls in the forrest…
I forget who it was that was collecting personal emails for a mailing list and why. I’ve been doing without anatabloc for years but I’ve been interested in this other source. Can someone catch me up on this? I’ve read buy one get two or something like that. Does it work the same? Dosing?
Just found out a dear friend was diagnosed with multifocal motor neuropathy. This woman did an Ironman last year. I’m thinking anatabloc might help as I think it’s an autoimmune disease.
TIA
Today's news release from MyMD is a major disappointment as they previously have said that preliminary results of the study were expected to be available by mid-year!
A Miami Florida spitting image of MyMD is LGVN. Only 5 million shares outstanding.
Longeveron Inc., LGVN a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions.
The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Market for rat costumes is heating up. Personally, I don't think MyMD will fall for it.
The New England Journal of Medicine sent me an email advertizing a new service they are offering, called "NEJM Catalyst (Innovations in Care Delivery)". On reading their description of the new service, my reaction was that it would be perfect for the coming introduction of MYMD-1.
Ironically, I had recently GOGGLED the most significant medical journals,and NEJM was right up there with the best, and had thought wouldn't it be great if it was the journal that was publishing the healthy life extension rat study.
B and B a tells us that the promised MYMD corporate profile will be broadcast widely soon. So we have this broadly broadcast corporate profile, the release of the preliminary results of the 2 human studies in progress, the publication of the healthy life extension rat study, and a new service from NEJM focussed on "Innovations In Care Delivery", all conviently adding up to a broad introduction by Jonnie and his team, of MYMD's focus of treating medical conditions and diseases rather than just treating symptons!
Perhaps that is why the WSJ website is still showing the one and only investor BUY signal with a price projection of $1,536.00 a share. It was posted last fall, and the price was predicted to be achieved within a year.
Pipe dream! Could be! Hope not!
Coming Soon from the letter to shareholders in December-We are producing an educational segment for VIEWPOINT, a short-form documentary series hosted by Dennis Quaid. Our 5-6-minute corporate profile will be broadcast by PBS with primetime distribution to public television stations in all 50 states in over 84 million homes via MSNBC, CNBC, CNN, Fox Business Network, The Learning Channel, and the Discovery Channel. The segment will be filmed at Johns Hopkins University Medical School.
Back in 2016 the "old" MYMD website stated that MYMD saw their mission as a company was to teach the medical industry and the pharmaceutical industry how to "treat disease" as opposed to just "treating the symptoms of disease".
I believe that that "teaching moment" is about to begin as the preliminary results from the first 2 human studies are revielled, and the publication in a suitable medical journal of the results of the preclinical lab rat study on "healthy aging" is published!
It remains to be seen if these results will make any difference in the price of MYMD, but I do believe that the healthy aging rat study will get a blizzard of attention as the public gets a vision of a drug in pill form that will deliver a longer and healthier lifespan!
European patent granted (cannibis & cannibinoids)
https://register.epo.org/application?number=EP19756525
EP3755318 - GENETICALLY MODIFIED CANNABIS SATIVA PLANTS AND MODIFIED CANNABINOID COMPOUNDS FOR TREATMENT OF SUBSTANCE ADDICTION AND OTHER DISORDERS
Can anyone offer some insight as to why MYMD was up nearly 5.5% on nearly 110K shares on a day when the averages plummeted!
See the last pr from the company
I've added the only really new thing: the 10000% gain projection should MYMD-1 capture one-eighth of the TNF-alpha blocker market.
Leifsmith Would appreciate your summary as I do not really understand what is going on here. Any help would be good.
"I wrote a much longer summary but iHub spontaneously erased it and required me to start over. No time left."
John’s Hopkins is involved w phase 2 - Clinical Trials.gov
3 Recruiting Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty
Conditions:
Sarcopenia
Frailty
Aging
Interventions:
Drug: MYMD-1 600MG
Drug: MYMD-1 750mg
Drug: MYMD-1 900mg
(and 5 more...)
Locations:
Clinical Research of West Florida, Inc
Clearwater, Florida, United States
Clinical Research of West Florida
Tampa, Florida, United States
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Ray Blanco on MYMD-1
Blanco tells us what most of us got from the last press release, but adds that if MYMD-1 gets just an eighth of the $40 billion market for TNF-alpha blockers, the possible gain exceeds 10,000% from the current price of the stock.
He sees a "huge catalyst" when the company reports Phase 2 results in mid-2022.
(I wrote a much longer summary but iHub spontaneously erased it and required me to start over. No time left.)
WHOA !!!!! THAT'S FANTASTIC NEWS IF IT'S TRUE !!!!! RAY'S COMPANY IS LOCATED IN BALTIMORE, JUST A SHORT DISTANCE FROM MyMD PHARMA'S HEADQUARTERS AND IS PROBABLY CLOSER TO WHAT'S GOING ON THERE THAN ANY OTHER OUTSIDER !!!!!
Does anyone have access-“The Tiny #Biotech That Could Unseat The World’s Best-Selling Drug” - Thank you, @RayBlancoSFP, for featuring MYMD Pharmaceuticals in your latest Catalyst Trader newsletter.
Learn more about the newsletter: stpaulresearch.com/publications $MYMD #Health #Science #Aging #Cannabinoid
I don't know where or if Patrick Cox is publishing.
Looks to me that John Mauldin is making use of Patrick's research.
An earlier post here has pointed to an article by Mauldin, and a lot of what he covers are things Patrick is watching.
Leif
Where is Patrick Cox today?
He use to be prolific.
Why has he not written about MyMD?
Anatabloc was fabulous.
Johns Hopkins Magazine has posted the following article about inflammation being responsible for loss of smell with Covid 19.
https://hub.jhu.edu/2022/04/12/inflammation-causes-covid-19-loss-of-smell/?utm_source=Hub+subscribers&utm_campaign=9603a68f4a-EMAIL_CAMPAIGN_2022_04_12_04_30_COPY_01&utm_medium=email&utm_term=0_d8bf41c16e-9603a68f4a-71566960&mc_cid=9603a68f4a&mc_eid=aca893738c
NR 12Apr2022 on MYMD-1 & Arthritis
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis
https://www.businesswire.com/news/home/20220411005985/en/
Seems like a reasonable assumption.
I am assuming that this is the material that MYMD will be presenting at an upcoming Arthritis Foundation event, to be followed by an application for a Phase 2 study of MYMD-1 vs Rheumatoid Arthritis! I'm also assuming that The Arthritis Foundation will be providing some of the funding for the Phase 2 study.
Minor news release this morning
10:39 AM EDT, 04/12/2022 (MT Newswires) reported that a preclinical study for the treatment of rheumatoid arthritis bested the effect competitive therapies by 30% to 70%, and also said that an IND was planned in H2 of this year.
I'd copy the release here except that it's copyrighted.
This is almost certainly a report on the trial we have been discussing. Perhaps released only to allow searches on "rheumatoid arthritis" to find it.
Great contribution to the subject of healthy life extension, but unfortunately would leave the average reader, in my opinion, totally confused because of all the unfamiliar terms.
I much prefer the explanation that focusses on the fairly recent discovery that the immune system and the metabolic system do not operate totally independently, as has long been taught, but at times work together and have been given the "new science" name IMMUNOMETABOLISM. When working properly together you have homeostasis, as in a young, healthy mammal. When not working properly together you have a condition known as "immunobolic disregulation".
Turns out that MYMD-1 gently nudges "immunometabolic disregulation" towards "homeostasis", reducing or correcting the resulting medical condition or disease.
Thus, as we age and disregulation occurs more frequently, MYMD-1 taken daily is there to "gently nudge disregulation back toward homeostasis" leading to longer and healthier aging.
Welcome to the EmpoweredPatientPodcast.com show. I'm Karen Jagoda, and my guest today is Dr. Adam Kaplin. He's the Chief Scientific Officer of MyMD Pharmaceuticals, mymd.com. And the topic today is extending the healthy human lifespan.
Thanks so much, Karen. Glad to be here and glad to be able to talk about what I hope are exciting topics in drug development related to aging.
Let's just start by talking a little bit about what the mission of MyMD is, particularly as it's related to extending the healthy human lifespan.
Sure. So, essentially what we have is a drug that gets to the cause of inflammation as one of its primary mechanisms of action. And since inflammation is involved in so many aspects of health and disease, health being fighting off infections, but disease sometimes getting confused and fighting off the body, which results in an autoimmune disease, like multiple sclerosis or thyroiditis, autoimmune thyroiditis, both of which this drug has been shown in preclinical studies to help.
But also, inflammation is involved in aging as well. So, probably one of the core features of pathological aging is chronic inflammation, that combined with some additional factors that I don't know if we're going to get into today. But for us, the exciting part is that we are going at the ability of this drug. Which is hopefully going to be coming out in a matter of months, a publication out of Hopkins that shows it delays aging in normal mice.
By delaying aging, what I mean is they not only lived longer, but they didn't lose their function. So, they retained their strength and their cognition. Because if we were only developing a drug that would just allow us all to get older and demented, that wouldn't be good for the economy, good for our personal health, good for anybody. So really, what we're excited about is the prospect of actually slowing the aging process and extending the healthy portion of our lifespans.
And the idea here is to not just treat age-related diseases but to delay the onset of those diseases. Is that right?
Yes so that's a really good way of putting it, Karen. Essentially what many people don't appreciate is that none of us are getting out of this life alive, so to speak, and what really gets us, in the end, is aging. So what I mean by that is if you completely eradicated all cancers, just gone, you have a fairy godmother who waves a magic wand, and all cancer is gone from human existence, you would extend the human lifespan by two, maybe three years.
Extending the Healthy Human Lifespan
by Addressing the Cause of Inflammation
with Dr. Adam Kaplin MyMD Pharmaceuticals
An Empowered Patient Podcast Published April 5, 2022
Dr. Adam Kaplin MyMD Pharmaceuticals Page 1 of 6 EmpoweredPatientPodcast.com
©TBI LLC 2022
Dr. Adam Kaplin:
Dr. Adam Kaplin:
Karen Jagoda:
Dr. Adam Kaplin:
Dr. Adam Kaplin:
Dr. Adam Kaplin:
Dr. Adam Kaplin:
And then you say, "Well, gee, that's a small percentage. How come only that amount?" Well, the reason why is if you sort of look at a graph, that with time the risk of getting cancer goes up, but right behind it is the risk of getting some pulmonary disease. Some lung disease, some heart disease, some brain disease. And if one falls, then the other one is right behind it. So, really what gets us is the aging process.
So the idea is if you want to make some major breakthroughs in extending people's function and quality of life and longevity, you really have to go after aging. Because any one of these other diseases is only going to clear the way for the next one in line.
And the idea here is that aging is somehow related to inflammation. And so tell us a bit about what your lead clinical compound, MYMD-1, is doing and what it is affecting?
Sure. Great question. So, aging probably is going to end up being the result of two primary processes. One is inflammation, and that is the product of having an immune system which is all set up to fight off infection. And not just fight off infection -- it turns out, inflammation is also a part of how we develop. So having the ability to get rid of neurons that are not connected ... we're born with way more neurons than we possibly need. And the ones that don't connect, you want to get rid of. Because you don't want them cluttering things up.
That also is done by the cleanup crews in the brain, which turns out to be the immune system of the brain, microglia. Inflammation is one of the core parts of development but also aging. If the inflammation is chronic and goes up over time, it can lead to accelerated aging.
Then the other part is that we burn fuel. All of our cells, in order to have the energy to do the things they do, need to burn fuel. And that's mostly glucose. And then, for storage reasons, fats. In burning fuel, we make some byproducts that are not so good. These byproducts can be injurious to cells. They're often called free radicals, and they cause free radical damage or oxidative injury to cells from these byproducts. So, this free radical combined with inflammation is probably the cornerstone of this aging process.
Now the drug that we have is unique in several factors. The easiest to understand, I think, the one we have the most data on, is the fact that it is a TNF-a inhibitor. TNF-a is tumor necrosis factor alpha. It is a cytokine, meaning it is what communicates between two immune cells. Just like two neurons have neurotransmitters, immune cells have the cytokines to communicate.
Extending the Healthy Human Lifespan
by Addressing the Cause of Inflammation
with Dr. Adam Kaplin MyMD Pharmaceuticals
An Empowered Patient Podcast Published April 5, 2022
Dr. Adam Kaplin MyMD Pharmaceuticals Page 2 of 6 EmpoweredPatientPodcast.com
©TBI LLC 2022
Dr. Adam Kaplin:
Karen Jagoda: Dr. Adam Kaplin:
Dr. Adam Kaplin:
Dr. Adam Kaplin:
Dr. Adam Kaplin:
But TNF-a turns out to be the master regulator of the immune system. It's the first one to go up if you get infected with any bacteria, fungus, or virus. And it also is up chronically in a number of autoimmune diseases. In fact, so much so that the number one grossing drug in the world is HUMIRA which is a drug that inactivates TNF-a. So we think that ours has certain advantages over the existing TNF-a inhibitors. Can I tell you what those are?
Yes. Please.
First of all, MYMD-1, our lead drug, can cross the blood-brain barrier. And that's a big deal because all of the existing TNF-a inhibitors are large molecules, large building blocks of immune globulins -- antibodies essentially -- or strung together series of receptors to TNF-a. So they just go out there, and they soak up TNF-a. They're like a specifically targeted sponge that just grabs TNF-a wherever it sees it.
But these large molecules can't get into the brain. Why is that a big deal? Well, it turns out that these molecules can have really toxic effects sometimes. For instance, we know that there is an MS-like condition that can be created by being on these drugs. And I've actually seen this in the clinic. Which is if you get put on this type of drug, not commonly, but certainly occasionally, it can have toxic effects. Those cells, when they cross over into the brain, see this very high level of TNF-a, and they sometimes get overactivated. Then they can lead the inflammation and damage in the CNS. We don't have that with MYMD-1.
The second most important thing I think is that these drugs, the anti-TNF-a treatments like HUMIRA, do not have any benefit for the brain. I mean, they can cause things that look like MS, but they certainly have no benefit for CNS inflammatory conditions. And among those are MS, lupus, but also dementias. Alzheimer's now has been implicated to have inflammation involved. So, crossing over the blood-brain barrier's a big deal. It's orally available. Additionally, all the other TNF-a inhibitors have to be taken by a needle in some way, injection or infusion.
And they're selective. So what is really interesting about the selectivity of our MYMD-1 drug is that TNF-a, as I say, is the first harbinger, first mobilizer of the immune system. If you get an infection for any reason, something crosses your gut or into your blood and crosses the blood barrier. So you want TNF-a around when it's produced in the blood by what are called monocytes or macrophages. You don't want it overexpressing itself when involved in autoimmune disease like B and T lymphocytes.
Extending the Healthy Human Lifespan
by Addressing the Cause of Inflammation
with Dr. Adam Kaplin MyMD Pharmaceuticals
An Empowered Patient Podcast Published April 5, 2022
Dr. Adam Kaplin MyMD Pharmaceuticals Page 3 of 6 EmpoweredPatientPodcast.com
©TBI LLC 2022
Dr. Adam Kaplin:
Karen Jagoda: Dr. Adam Kaplin:
Dr. Adam Kaplin:
Dr. Adam Kaplin:
Dr. Adam Kaplin:
Karen Jagoda:
Well, it turns out, our drug only inhibits the production of TNF-a in B and T cells, not in macrophages. And that's, again, a big deal. Because a lot of the bad things that can happen from the anti-TNF antibody treatment that currently exists are that they can cause severe infection, like pneumonia, and up to and including death and there is a black box warning on these drugs. The fact that we don't inhibit the macrophages suggests that we won't have that problem.
What did you learn from COVID-19 when it comes to cytokine storms?
Yes. So again, great question. The first thing I think that we've all learned is that thank God this only happens once every hundred years, God willing. But what we've all learned is that this inflammation is what really is the problem. It's not the virus itself that causes and unleashes this incredibly toxic effect on the lungs. It's what happens when it leads to overactivation of the immune system, and it's the immune system that really melts the lungs in really awful cases of COVID-19.
And this inflammation is known to show up, as you say, as a cytokine storm. This is because the immune system just gets way too activated and overexcited when it sees this virus, and it's trying to fight it off. There's all of this kind of bystander injury. Imagine that if you're in a war and you have these big bombs, and you set them off, and they're going to blow up not just the target but the surrounding targets. And that's what happens here with COVID-19 and inflammation.
And one of the things that we know is it does affect the brain. For instance, we know that three months after COVID infection, 50% of people will have clinical depression. A significant proportion of that group will also have cognitive impairment, this fuzziness that is often part of long hauler syndrome, which has been characterized in about 10% of patients --but probably is present in a higher percentage of patients.
So being able to call off this chronic immune process is critical in being able to weather storms like COVID-19, which is more of an acute leading to a chronic condition. It's an accelerated vision of what we've been going after to try to calm down autoimmune diseases and delay the inflammation in the tissue with pathological agers.
Where are you in clinical trials with MYMD-1?
Extending the Healthy Human Lifespan
by Addressing the Cause of Inflammation
with Dr. Adam Kaplin MyMD Pharmaceuticals
An Empowered Patient Podcast Published April 5, 2022
Dr. Adam Kaplin MyMD Pharmaceuticals Page 4 of 6 EmpoweredPatientPodcast.com
©TBI LLC 2022
Dr. Adam Kaplin:
Dr. Adam Kaplin:
Dr. Adam Kaplin:
Karen Jagoda: Dr. Adam Kaplin:
Dr. Adam Kaplin:
Dr. Adam Kaplin:
Yes, so we've been fortunate enough to get through the phase I study, which means we've used MYMD-1 in healthy volunteers, and it had no major side effects. So, although, again, there is a relatively small number of people that you use in phase I studies, there were no side effects really of any significance. And what we ended up then being able to do is get the FDA permission to do an investigational new drug trial, examination for sarcopenia.
Sarcopenia is muscle wasting. So what happens to people with excessive sarcopenia is they have lots and lots more chances to fall and break a hip and the like. It's been shown by, in fact, a world-class group of researchers, led by Jeremy Walston at Johns Hopkins, that the level of inflammation, specifically elevated TNF-a receptor 1, one of the receptors for TNF-a, is a hallmark of sarcopenia. A very good readout, biomarker if you will, of pathological aging.
So, we are taking patients who have elevated levels of TNF and TNF-a receptor I. And we are then seeing the ability of MYMD-1 to slow that process down and decrease the inflammation. Then eventually, look at its effect on muscle wasting, and see if we can preserve muscle function and strength in patients who are at risk of losing that as they age.
Do you see MYMD-1 being used in conjunction with other drugs that are out there to address very specific elements of the aging process?
So right now, certainly, if you're talking about drugs that have had trials going on and in mammals. The drug that has perhaps the best data is rapamycin, which is an anti-inflammatory molecule used to prevent kidney and organ rejection after transplant for instance. Another drug is also resveratrol, which is the substance that got a lot of publicity as being in red wine. And again, these are drugs that have been studied to delay aging.
What I can tell you is from the study done at Hopkins, although these results are not even published. But I can just perhaps pique your interest and let you know the preliminary results. Compared to rapamycin, MYMD-1 was four times better at preventing the aging process. And resveratrol has an even smaller effect than rapamycin.
So there have been other ways, dietary ways of prolonging life. But of course, medications, but there really aren't many out there that have shown any significant benefit in mammals. And so we are, to our knowledge, one of the first, if not the only FDA approved, double-blind study of aging-related processes that are into testing in mankind.
Extending the Healthy Human Lifespan
by Addressing the Cause of Inflammation
with Dr. Adam Kaplin MyMD Pharmaceuticals
An Empowered Patient Podcast Published April 5, 2022
Dr. Adam Kaplin MyMD Pharmaceuticals Page 5 of 6 EmpoweredPatientPodcast.com
©TBI LLC 2022
Dr. Adam Kaplin:
Karen Jagoda:
What I mean is that the FDA doesn't look at aging as a disease. Because it's understandable from their standpoint, aging is a part of the life process. As they say, none of us are getting out of this life alive. What they do allow is not for aging, but they allow us to look at pathological processes as our target, like sarcopenias which is a form of advanced pathological aging. Really, this is the best that we can do, given that there are no drugs out there that have been approved to delay aging.
Thanks to my guest today, Dr. Adam Kaplin, Chief Scientific Officer at MyMD Pharmaceuticals, mymd.com. Follow them on Twitter @MyMDPharma. I'm Karen Jagoda, and you've been listening to the EmpoweredPatientPodcast.com show. Follow me on Twitter @KarenJagoda. Like us on Facebook at Empowered Patient Radio. Thanks for listening, and we'll see you next time.
Extending the Healthy Human Lifespan
by Addressing the Cause of Inflammation
with Dr. Adam Kaplin MyMD Pharmaceuticals
An Empowered Patient Podcast Published April 5, 2022
Accelerates the pace, but not the price. Looks like it's going to take some definite proof of benefit to move this incredible stock!
NR today: MyMD Pharmaceuticals Accelerates Pace
https://www.businesswire.com/news/home/20220405005376/en/
A quick reading of the Annual Report left me with a recollection of the following paragraph.
" Sales and Marketing
MyMD does not currently have sales and marketing infrastructure to support the launch of its products. MyMD intends to build such capabilities in North America prior to launch of MYMD-1. Outside of North America, MyMD may rely on licensing, co-sale and co-promotion agreements with strategic partners for commercialization of its products."
I had posted previously that I thought their best chance for success was to demonstrate MYMD-1's value through successful Phase 2 studies, then license them to appropriate international pharmaceutical companies in exchange for progress payments and royalties. The quoted paragraph above seems like a good alternative.
Recommended search: "https://duckduckgo.com/?q=patrick+cox+anatabine+story&t=osx&ia=web"
Or whatever search engine you happen to use.
I've saved long articles by Patrick that I cannot post here due to copyright restrictions. Much of what Patrick has written about Anatabloc (anatabine citrate) is probably pertinent to MYMD-1.
Thank you! Patrick Cox and John Mauldin
Patrick Cox was once a writer for Mauldin's newsletters, and at that time Patrick was writing about Star Scientific and its successor, Rock Creek Pharmaceuticals, and their anatabine citrate molecule sold as Anatabloc.
Anatabloc, like MYMD-1, was a TNF-alpha blocker synthesized to match an alkaloid molecule found in tobacco.
The claims being made by MyMD about MYMD-1 are the same as those made for Anatabloc, and the way the two molecules work seems to be similar.
However, Patrick Cox has told me that MYMD-1 is a far superior molecule. In exactly what way is not clear to me yet.
Both molecules owe their origins to some of the same people, including entrepreneur Jonnie Williams, and a group of scientists at Johns Hopkins.
But there are new players in top positions at MyMD, and they seem to know what they are doing.
I'm extremely optimistic about the future of this company.
Pictures of the two molecules, Anatabloc and MYMD-1:
In biology. small insignificant variations in molecules can have enormous consequences. That may be the case here.
GREAT FIND !!!!! MUCH THANKS FOR SHARING.
JOHN MAULDIN ON BOARD!
The legendary economist John Mauldin revealed in a recent article that he is a believer in, and a shareholder of, MYMD. Mauldin is the founder of Mauldin Economics, a financial expert, and NY Times best-selling author. In a March 25 Thoughts from the Frontline article, he summarized the MYMD story and disclosed his ownership interest:
Let’s start with some very new research from a company called MyMD Pharmaceuticals. (Full disclosure: I am an investor but have no other financial relationship with the company.) This is clearly in the fountain of middle age category.
Their drug, MYMD-1 is a TNF-a inhibitor, like Humira and the other monoclonal antibodies (mAbs) that make up a $25 billion market treating multiple serious diseases. Unlike mAbs, which are grown from human or animal cells, MYMD-1 is a synthesized version of a naturally occurring molecule found in plants. It's also safer than the mAbs that come with a black box warning indicating serious risk. Moreover, it doesn’t have to be injected. It is a simple pill and, based on a phase 1 human trial, has virtually no side effects.
The most important thing about TNF-a is that it is a major driver of aging itself.
Link to full article:
https://www.mauldineconomics.com/frontlinethoughts/things-are-getting-better#healthcare
Noticed that. Like it.
"WUS UP". Consistent 3-day buying on moderate volume with no news !!!
Thanks for the link. No science in this interview, but enough there to get someone interested in learning more. There's plenty of science to be found.
Here is the link to Dr. Adam Kaplin's presentation on "Cheddar Innovates"
https://cheddar.com/media/this-anti-aging-drug-is-disrupting-a-600-billion-industry
MyMD on Cheddar News Network today
https://www.businesswire.com/news/home/20220324005631/en/
Sarcopenia/Frailty study posted on St. Patrick's Day.
https://clinicaltrials.gov/ct2/show/NCT05283486
"Not Science Fiction Anymore?" - MYMD-1, Benzinga
"Not Science Fiction Anymore? MyMD Moves Into Phase 2 Research For A Pill To Reportedly Slow Down Aging" by Rachael Green
"[the company] hopes to move closer toward making MYMD-1 the first treatment to be approved by the Food and Drug Administration (FDA) to treat aging." —a remarkable statement, imo.
https://www.benzinga.com/general/biotech/22/02/25682430/not-science-fiction-anymore-mymd-moves-into-phase-2-research-for-a-pill-to-reportedly-slow-down-a
"Rachael Green is a New York-based freelance writer with a strong background in media and journalism, having worked as a reporter, associate producer, or writer for the past 9 years. She specializes in finance, health, business news, and politics with a focus on crafting research-driven ..."
https://www.benzinga.com/author/rachael-green
Followers
|
18
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
547
|
Created
|
04/19/21
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |